Clinical efficacy of modern emollients in atopic dermatitis: case report



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atopic dermatitis is the common chronic inflammatory disorder, characterized by skin irritation, itch, often accompanied by respiratory allergy symptoms - allergic rhinitis and bronchial asthma. AD prevalence varies between 15-30% in children and 2-14% in adults in industrialized countries. The pathophysiology of atopic dermatitis is complex encompassing genetic predisposition to allergy, dysregulation of innate and adaptive immunity and environmental risk factors. Recent genetic and molecular research has focused interest on skin barrier function and it’s role in AD pathogenesis. It has been established that disruption of the epidermal barrier leads to increased permeability of the epidermis, pathological inflammation in the skin, and percutaneous sensitization to allergens. Thus, most novel treatment strategies seek to target immune therapy, repair of epidermal barrier and prevention of sensibilization and atopic march. The article is devoted to skin barrier function disruption in AD and beneficial role of emollients in skin care; clinical case is presented.

Full Text

Restricted Access

About the authors

E V Smolnikov

NRC Institute of Immunology FMBA of Russia

Email: qwertil2010@yandex.ru

A O Litovkina

NRC Institute of Immunology FMBA of Russia

O G Elisyutina

NRC Institute of Immunology FMBA of Russia

E S Fedenko

NRC Institute of Immunology FMBA of Russia

References

  1. Mortz CG, Andersen KE, Dellgren C., Barington T., Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70:836-845. DOI: 10.1111/ all.12619.
  2. Asher MI, Montefort S., Bjorksten B., Lai CK, Strachan DP, Weiland SK et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-743.
  3. Намазова-Баранова ЛС, Баранов АА, Кубанова АА, Ильина НИ, Курбачёва ОМ, Вишнёва ЕА и соавт. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии. Вопросы современной педиатрии. 2016;15(3):279-294
  4. Vinding GR, Esmann S., Jemec GB. Quality of life in atopic dermatitis: changes over 6 years in patients who report persistent eczema. J. Dermatol. 2012;39:721-722. doi: 10.1111/j.1346-8138.2012.01512.x.
  5. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J. Dermatol. 1998;139:73-76.
  6. Arkwright PD, Motala C., Subramanian H., Spergel J., Schneider LC, Wollenberg A. et al. Management of difficult-to treat atopic dermatitis. J. Allergy Clin Immunol in practice. 2013:1(2):142-151. doi: 10.1016/j.jaip.2012.09.002. Epub 2012 Dec 14.
  7. Williams HC, Burney PG, Pembroke AC Hay RJ. The UK Working Party’s Diagnostic Criteria for atopic dermatitis. III. Independent hospital validation. Br J. Dermatol. 1994;131:406-416.
  8. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9:244-253. doi: 10.1038/nrmicro2537.
  9. Byrd AL, Deming C., Cassidy SK, Harrison OJ, Ng WI, Conlan S. et al. Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci Transl Med. 2017;9:eaal4651. doi: 10.1126/scitranslmed. aal4651.
  10. Kobayashi T., Glatz M., Horiuchi K., Kawasaki H., Akiyama H., Kaplan DH et al. Dysbiosis and Staphylococcus aureus colo nization drives inflammation in atopic dermatitis. Immunity. 2015;42:756-766. doi: 10.1016/j.immuni.2015.03.014.
  11. Draelos ZD. Clinical situations conducive to proactive skin health and anti-aging improvement. J. Investig Dermatol Symp Proc. 2008;13(1):25-27. doi: 10.1038/jidsymp.2008.9.
  12. Jungersted JM, Hellgren LI, Jemec GB, Agner T. Lipids and skin barrier function - a clinical perspective. Contact Dermatitis. 2008;58(5):255-262. doi: 10.1111/j.1600-0536.2008.01320.x.
  13. Bonte F. Skin moisturization mechanisms: new data. Ann Pharm Fr. 2011;69(3):135-141. doi: 10.1016/j.pharma.2011.01.004.
  14. Draelos ZD. New channels for old cosmeceuticals: aquaporin modulation. J. Cosmet Dermatol. 2008;7(2):83. doi: 10.1111/j.1473-2165.2008.00367.x.
  15. Brown SJ, Irvine AD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg. 2008;l(27):128-137. DOI: 10.1016/j. sder.2008.04.001.
  16. Kezic S., O’Regan GM, Yau N. et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy. 2011;66(7):934-940. doi: 10.1111/j.1398-9995.2010.02540.x.
  17. Mizutani Y., Mitsutake S., Tsuji K., Kihara A., Igarashi Y. Ceramide biosynthesis in keratinocyte and its role in skin function. Biochimie. 2009;91(6):784-790.
  18. Lebwohl M., Herrmann LG. Impaired skin barrier function in dermatologic disease and repair with moisturization. Cutis. 2005;76(6 suppl):7-12.
  19. Hara-Chikuma M., Verkman AS. Roles of aquaporin-3 in the epidermis. J. Invest Dermatol. 2008;128(9):2145-2151. doi: 10.1038/jid.2008.70.
  20. Boury-Jamot M., Daraspe J., Bonté F., Perrier E., Schnebert S., Dumas M. et al. Skin aquaporins: function in hydration, wound healing, and skin epidermis homeostasis. Handb Exp Pharmacol. 2009;(190):205-217. doi: 10.1007/978-3-540-79885-9_10.
  21. Kobayashi T., Glatz M., Horiuchi K., Kawasaki H., Akiyama H., Kaplan DH et al. Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity. 2015;42:756-766. doi: 10.1016/j.immuni.2015.03.014.
  22. Christophers E., Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res. 1987;279:S48-51.
  23. Ong PY, Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. 2002;347(15):1151-1160. doi: 10.1056/NEJMoa021481.
  24. Danuta N., Ewelina G. The Role of Immune Defects and Colonization of Staphylococcus aureus in the Pathogenesis of Atopic Dermatitis. Anal Cell Pathol (Amst). 2018:1956403. doi: 10.1155/2018/1956403.
  25. Снарская ЕС, Кряжева СС, Лавров А.А. Роль толл-подобных рецепторов (TLR) активаторов врожденного иммунитета в патогенезе ряда дерматозов. Росс журн кож и вен болезней. 2012;2:9-12
  26. Lomholt H., Andersen KE, Kilian M. Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis. J. Invest Dermatol. 2005;125:977-982. doi: 10.1111/j.0022-202X.2005.23916.x.
  27. Garg A, Chren MM, Sands IP, Matsui MS, Marenus KD, Feingold KR et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol. 2001;137:377-382.
  28. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. DOI: 10.1016/j. jaad.2014.03.023.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2018



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies